

Table 2 showing prevalence of components of metabolic syndrome

MetS Component	Prevalence (%)
Hypertriglyceridemia	82
Central Obesity	72
Low HDL	65
Hypertension	22
Hyperglycemia	8




Figure 1 showing prevalence of metabolic syndrome components

DISCUSSION

This study highlights a significant association between metabolic syndrome (MetS) and subclinical carotid atherosclerosis in young adults aged 18–40 years. One-third (33%) of participants demonstrated increased carotid intima-media thickness (CIMT), indicating early vascular changes despite their relatively young age. This finding is consistent with previous studies, such as those by Lorenz et al. and Nagamatsu et al., which established CIMT as a reliable early marker of cardiovascular risk, particularly in individuals with metabolic abnormalities.^[6,21]

Among the components of MetS, hypertriglyceridemia was the most prevalent, observed in 82% of patients. Elevated triglyceride levels are known to promote endothelial dysfunction, oxidative stress, and systemic inflammation—all of which are integral to atherosclerosis development^[14] Similarly, low HDL cholesterol, present in 65% of the cohort, likely contributed to atherosclerosis due to its reduced ability to mediate reverse cholesterol transport and its anti-inflammatory properties.^[18] These lipid abnormalities showed a strong correlation with increased CIMT, underscoring the critical role of dyslipidemia in the early stages of atherosclerotic disease.

Central obesity, present in 72% of the participants, also emerged as a major contributor to increased CIMT. Abdominal adiposity is metabolically active and strongly associated with insulin resistance, chronic low-grade inflammation, and adverse lipid profiles—all of which drive atherosclerotic changes.^[16,17] These findings reinforce the hypothesis that visceral obesity is a key early driver of cardiovascular risk in MetS.

Interestingly, hypertension and hyperglycemia—traditionally considered major cardiovascular risk factors—were less prevalent in this cohort, seen in only 22% and 8% of patients, respectively. This suggests that in younger individuals, lipid abnormalities and obesity may precede the development of glucose intolerance and elevated blood pressure in the progression of MetS, a sequence supported by previous metabolic cascade models.^[18]

Gender differences were also noted, with a higher proportion of males exhibiting increased CIMT. This aligns with existing literature indicating that men are more likely to develop atherosclerotic disease earlier than women, potentially due to differences in hormonal protection, particularly estrogen in premenopausal females, and lifestyle risk factors such as tobacco and alcohol use, though these were not assessed in this study.^[19]

Comparing the present findings with global and Indian studies, such as those by Grundy et al., Misra et al., and the ARYA study, similar trends in the predominance of central obesity and dyslipidemia in MetS-associated vascular changes are evident. The results further emphasize the need for early identification of at-risk individuals using non-invasive tools like carotid ultrasound, particularly in resource-limited settings where preventive strategies can significantly reduce future cardiovascular burden.

In summary, this study underscores the early onset of vascular changes in young adults with MetS, driven primarily by dyslipidemia and abdominal obesity. These findings highlight the urgent need for early lifestyle and pharmacological interventions to delay or prevent cardiovascular events later in life.

CONCLUSION

This study confirms a significant association between MetS and subclinical carotid atherosclerosis in young adults. Central obesity, hypertriglyceridemia, and low HDL cholesterol were the most influential components linked to increased CIMT.

REFERENCES

- Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JJ, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement. *Circulation*. 2009;120(16):1640–5.
- Grundy SM. Metabolic syndrome pandemic. *Circulation*. 2008;117(5):628–35.
- Mottillo S, Filion KB, Genest J, Joseph L, Poirier P, et al. The metabolic syndrome and cardiovascular risk. *J Am Coll Cardiol*. 2010;56(14):1113–32.
- Bots ML, Hofman A, Grobbee DE. Common carotid intima-media thickness and lower extremity arterial atherosclerosis. *Arterioscler Thromb Vasc Biol*. 1997;17(8):1672–8.
- O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke. *N Engl J Med*. 1999;340(1):14–22.
- Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness. *Circulation*. 2007;115(4):459–67.
- D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care. *Circulation*. 2008;117(6):743–53.
- Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. *J Clin Endocrinol Metab*. 2008;93(11 Suppl 1):S9–30.
- Singh GM, Danaei G, Farzadfar F, Stevens GA, Woodward M, Wormser D, et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases. *Lancet*. 2013;382(9894):1397–408.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel. *JAMA*. 2001;285(19):2486–97.
- Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim intima-media thickness consensus. *Cerebrovasc Dis*. 2004;18(4):346–9.
- Jayaraman M, Devaprasad M, Sundaram A, Arulprakash P. Evaluation of subclinical atherosclerosis by carotid intima media thickness in patients with metabolic syndrome. *Indian J Endocrinol Metab*. 2018;22(5):637–41.
- Bansal M, Sharma P, Bansal M, Mehrotra R, Mehrotra S. Carotid intima media thickness as a marker of atherosclerosis in metabolic syndrome. *J Clin Diagn Res*. 2016;10(1):OC14–8.
- Kwiterovich PO Jr. Recognition and management of dyslipidemia in children and adolescents. *Pediatr Rev*. 2000;21(10):321–35.
- Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. *N Engl J Med*. 2007;357(13):1301–10.
- Després JP. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. *Eur Heart J Suppl*. 2006;8(Suppl B):B4–B12.
- Neeland JJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes. *JAMA*. 2012;308(11):1150–9.
- Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. *JAMA*. 2002;287(3):356–9.
- Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. *N Engl J Med*. 1999;340(23):1801–11.
- Ferreira I, Twisk JW, van Mechelen W, Kemper HC, Stehouwer CD. Intima-media thickness in adolescents. *J Hypertens*. 2004;22(9):1779–86.
- Nagamatsu H, Nakamura Y, Tada H, Okada H, Satoh M, Naito R, et al. Early vascular changes in young adults with metabolic syndrome. *J Atheroscler Thromb*. 2023;30(3):319–27.